LYT-100 was well-tolerated compared to pirfenidone in a healthy older adult crossover trial, informing dose selection for recently initiated trial in IPF PureTech Health plc (Nasdaq: PRTC, LSE:
HUTCHMED (China) (HCM) to Present Additional Fruquintinib MRCT FRESCO-2 Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.